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Introduction
Cheyne-Stokes respiration is an event observed in patients 
with cardiopathies and brain/neurological diseases. It affects 
around 40% of stable cardiopaths with an ejection fraction (EF) 
< 45%1. It is a sign of heart failure severity, being associated 
to an increase in the sympathetic stimulation, which is a 
known poor prognosis factor in these patients2. Although it 
can be observed during the state of wakefulness, its diagnosis 
is achieved through polysomnography and consists of: 
- At least 03 consecutive cycles of an increasing-decreasing 
alteration in the respiratory range. 
- One or both of the following: 
D,QGH[RIFHQWUDODSQHDK\SRSQHDSHUKRXU
b) The increasing-decreasing cyclic alteration of the 
respiratory range lasts at least 10 consecutive minutes3
(Figure 1).
The mechanisms that lead to Cheyne-Stokes respiration 
(CSR) have yet to be completely clarified. It is known that these 
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Fig. 1 - Cheyne-Stokes respiration: observe the increasing-decreasing pattern associated to central apnea (absence of abdominal and thoracic effort), leading to a 
decrease in the oxyhemoglobin saturation and awakening.
patients are hypocapnic, which would cause the occurrence 
of central apnea. Several reasons for this chronic hypocapnia/
hyperventilation are speculated: a higher sensibility of the 
respiratory CO2 chemoreceptors; low body oxygen stores, 
leading to respiratory instability and hyperventilation; 
interstitial pulmonary edema due to high lung capillary 
pressure. The increase in the circulatory time of patients 
with congestive heart failure (CHF) is also implicated in the 
physiopathology of CSR, as the delayed information of the lung 
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PaCO2 variation to the respiratory chemoreceptors would cause 
the typical oscillation of this type of respiration4.
A research on the subject at MEDLINE showed that 
Continuous Positive Airway Pressure (CPAP) is the most 
studied modality (40%). Oxygen therapy comprises 16% 
of the References. The treatment of CSR aims at fighting 
hypoxia and the nocturnal awakenings present during the 
respiration, which increase the sympathetic activity, as well 
as improving diurnal somnolence and heart function. The 
therapeutic modalities that will be shown subsequently try 
to attack one of the probable mechanisms that generate the 
respiration (Table 1).
CPAP
The CPAP has been extensively shown as the therapeutic 
modality of choice in Sleep Obstructive Apnea/Hypopnea 
Syndrome, where it has the function of preventing the 
collapse of the upper airways. However, in CSR, CPAP has 
other functions. It increases the body oxygen stores5 through 
the increment of the functional residual capacity, in addition 
to increasing PaCO2 by decreasing the current volume. By 
increasing the body oxygen stores of, it reduces the respiratory 
instability, which is responsible for the respiration variations. 
The elevation of PaCO2 impairs the occurrence of central 
apneas due to the increase in the difference between the 
patient’s PaCO2 and the PaCO2 of the apnea threshold. 
Krachman demonstrated the effects of the CPAP on body stores 
of O2. CPAP diminished the velocity of the oxyhemoglobin 
saturation decline (dSat/dt) caused by the apneas, a value that 
correlates negatively with the body oxygen stores5.
The positive pressure in the airways also acts by improving 
the ventricular function in patients with CHF by decreasing 
the pre- and post-load. 
Naughton demonstrated that CPAP reduces the left 
ventricle (LV) end-systolic transmural pressure (LVESTMP = 
systolic pressure of the left ventricle – esophageal pressure) 
and the product LVESTMP x cardiac frequency (an index of 
systolic myocardial power generation and O2 consumption), 
decreasing the LV load6. It has also been demonstrated that 
cardiopath patients with CSR have elevated pulmonary venous 
congestion and interstitial pressure7, which causes increased 
afferent vagal stimulation resulting in hyperventilation. CPAP 
also fights the interstitial edema.
Due to the fact that many of these patients snore, CPAP can 
also act by decreasing the airway resistance. In snorers, there 
is a higher decrease in the pleural pressure and therefore, a 
higher LV pre-load, which is corrected by making the airways 
more pervious with CPAP.
Several studies have shown the effects of CPAP on CSR 
of patients with cardiopathies, by reducing the central 
apnea/hypopnea index (AHI)2,5, 8-12, improving nocturnal 
oxyhemoglobin saturation (SatO2)
2,8-10,12, decreasing the time 
of CSR during sleep9 and the number of brief awakenings9-12,
increasing the percentage of slow-wave sleep9,12. Its effects 
are also maintained during the day as observed in the LV EF 
improvement2,11,12, in the NYHA classification of CHF2,9,11,12, in 
the reduction of diurnal somnolence at the Epworth scale and 
decreased heart frequency during the state of wakefulness11.
It also decreases the sympathetic activity by reducing the 
concentrations of nocturnal urinary norepinephrine and 
morning plasma norepinephrine2 and decreases the frequency 
of ventricular arrhythmias10.  It increases the heart transplant 
free-survival and decreases the mortality/heart transplant 
rate as shown in a study with more than 2 years of follow-
up13. As for quality of life, there was improvement in the 
“Chronic Heart Failure Questionnaire” score regarding the 
items dyspnea, fatigue, emotional well-bring, and disease 
domain11.
Not all patients respond to CPAP. Javaheri10 found a 
frequency of only 43% of responders (patients whose AHI 
decreased to less than 15 per hour). The non-responders 
had a mean AHI of 62 and the responders, a mean AHI of 
36, which shows that more severe patients may not respond 
to CPAP, probably due to the fact that the latter can lead to 
a tendency to wake up, promoting respiratory instability due 
to the more elevated pressures used in these patients. Other 
studies have found a higher frequency of responders, but they 
had less severe cohorts9.
Contrarily, other authors have shown that CPAP failed to 
improve CSR14,15, or even showed that it can be deleterious 
for these patients15. A methodological error that might have 
contributed to the lack of success of CPAP was the protocol 
used in pressure adjustment, initiated arbitrarily at 7.5 cmH2O
or higher.
Javaheri10 and Naughton et al11 created different ways 
to titrate the correct pressure, but both are in agreement 
about starting the titration with a pressure of 5 cmH2O and 
increasing the pressure gradually until a value that is tolerable 
by the patient is reached, trying to achieve between 10 to 
12 cmH2O. Another possible explanation for the absence of 
beneficial effects is the CPAP evaluation after just one night of 
its use14. It has been demonstrated that the benefits of CPAP 
are achieved with time (there is an increase in EF within 1 to 
3 months of use) and the pressure level can also be optimized 
during treatment. 
Table 1 - Effects on respiratory parameters and quality of sleep
Time in CSR SatO2 AHI Short awakenings Sleep efficiency Slow wave sleep
CPAP Ļ Ĺ Ļ Ļ Ĺ Ĺ
O2 Ļ Ĺ Ļ Ļ - Ĺ
Theophylline - ? Ļ Ļ - -
CPAP - Continuous Positive Airway Pressure; CSR - Cheyne-Stokes respiration; AHI - apnea/hypopnea index.
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Recently, an important multicentric study16 that involved 
258 patients evaluated long-term use (24 months) of CPAP 
in cardiopaths. The result, however, was not the expected 
one. Although it reduced the central apnea index, increased 
the oxyhemoglobin saturation, improved heart function and 
reduced the levels of plasma norepinephrine, CPAP failed in 
demonstrating benefits regarding mortality and transplant-
free survival. 
In the beginning of the study, the transplant-free survival 
curve favored the control group, but 18 months later it started 
to favor the CPAP group, with no statistical difference at 
the end of the study. These results that did not corroborate 
the expectations generated by previous studies can be a 
consequence of more frequent beta-blocker use in comparison 
to the older ones. The concomitance of CPAP use and beta-
blocker has limited the potential to improve the ventricular 
function obtained with CPAP alone. 
An undesirable adverse effect of CPAP is the cardiac output 
decrease and consequent arterial hypotension, which can 
be prevented with pressure titration from 5 cmH2O and its 
gradual elevation for days or weeks as tolerated by the patient. 
Another common complaint is the discomfort caused by the 
nasal mask.
Another method of ventilation with positive pressure (Bi-
level Positive Airway Pressure, BiPAP) was compared to CPAP, 
but did not show any advantage when compared to the latter, 
in addition to its very high cost9.
Oxygen
The main effects of O2 on CSR are: increase of body 
oxygen stores, preventing the instability of arterial gases and 
the removal of the hypoxic stimulus to hyperpnea allowing the 
increase of PaCO2, augmenting the difference between the 
patient’s PaCO2 and the PaCO2 of the apnea threshold
17.
Studies have shown the several benefits of O2 in 
CSR: AHI reduction18-22, improvement of the nocturnal 
SatO2
8,18-22, decrease in the mean time of CSR18,21 and brief 
awakenings18,20,22, increase of slow wave sleep18,22, reduction 
in cardiac frequency during the night20. It did not modify 
symptoms20,21, but improved a cognitive function parameter: 
the velocity of information processing20. It reduced the 
sympathetic activation demonstrated by the decrease of 
nocturnal urinary excretion of noradrenaline21. There was 
an increase in peak O2 consumption at the ergometric cycle 
test20, which is a strong predictor of mortality; this leads to 
speculations about the improvement of survival com O2.
Krachman et al8 compared O2 with CPAP in prospective 
randomized study with 25 patients and concluded that the 
two modalities of treatment are equally effective, although in 
this study CPAP as well as O2 were used for only one night.  As 
seen before, CPAP effect depends on its long-term use. 
The O2 flow used in these studies varied from 2 to 4 l/min 
and the response rate to O2 (percentage of those who had the 
AHI reduced to < 15 per hour) was 39%19. As with CPAP, the 
responders were those with milder CSR (lower AHI, milder 
oxyhemoglobin desaturation and higher PaCO2).
Theophylline
The mechanism through which Theophylline acts is 
uncertain. It is known that it inhibits phosphodiesterase, but 
at the concentrations used for the treatment of CSR, it does 
not have the inhibitory effect. At therapeutic concentrations, 
it competes with adenosine in some of its receptors. At the 
central nervous system (CNS), adenosine is a respiratory 
depressor and Theophylline has a respiratory stimulation effect 
as it competes with the first, preventing central apneas. 
It has been demonstrated that Theophylline reduced 
AHI23,24, improved nocturnal SatO2
23,24 and decreased total 
brief awakenings24 and those associated with respiratory 
alterations23. It did not alter sleep efficiency, sleep stages23,24,
or LV EF23. Additionally, it did not alter ventricular arrhythmias, 
suggesting that it is a safe option for these patients. It is 
important to know that Javaheri et al23 used O2 in patients due 
to oxyhemoglobin desaturation during examinations and this 
fact might have contributed to alterations in the results. 
The Theophylline doses used were: 200-300 mg/day (4.3 
mg/kg)24 and 3.3 mg/kg, twice a day23. Its defenders justify 
its use by mentioning the limitations of other therapeutic 
modalities: low adherence to CPAP and the possibility of 
inadvertently dislodging the O2 cannula during sleep. 
Other options
1) CHF drug therapy optimization: In fact, this should be 
the first-choice treatment, as it is the simplest. Walsh et al22
demonstrated that patients with stable CHF with the use 
of furosemide alone, showed increase of slow wave sleep 
and REM sleep, reduction of HAI and desaturation events, 
as well as CO2 increment at the end of the expiration and 
ventilation reduction a minute after the addition of captopril 
75 mg/day for a month. Dark et al25 studied patients who 
were admitted due to heart failure decompensation, showing 
respiratory pattern abnormalities (predominantly central apnea 
with CSR) in all of them. After CHF compensation during 
hospital stay with diuretics, vasodilators, antihypertensive 
drugs, antiarrhythmic drugs and positive inotropics, a new 
polysomnography was performed with decrease in AHI and 
a tendency of SatO2improvement.
2) Pacemaker: Left or biventricular pacemaker implant 
with atrial trigger mode26 showed a reduction in AHI and 
improvement in SatO2 as well as in the subjective quality 
of sleep, possibly due to cardiac function improvement. 
In this study, no patient had a conventional indication of 
pacemaker.
3) Benzodiazepine drugs: The reason for not using 
benzodiazepine drugs is the effect of increasing the awakening 
threshold, as it is a consequence of CSR and can be a 
perpetuating factor of the problem, due to hyperventilation 
and hypocapnia, caused by awakening. Studies have shown 
reduction of the brief awakenings, but no significant decrease 
in AHI or nocturnal SatO2
27,28. Special attention should be given 
to the patients with obstructive apneas, as the benzodiazepine 
drugs can aggravate them. 
4) CO2: The use of CO2 (0.2-1 l/min) mixed with O2 (2l/min) 
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during sleep has been studied, and showed decrease in the 
duration of CSR and improvement in SatO2, but decreased 
the quality of sleep and increased the sympathetic activity29.
Additionally, the resulting hypercapnia increases the left and 
right ventricular post-load. Therefore, it must not be indicated 
for patients with CHF. 
5) Adaptive servo-ventilation (ASV): This new ventilatory 
modality consists of a variable ventilatory support that adapts 
depending on the phase of the respiration, being higher in 
apnea and lower in hyperventilation periods. It corrected CSR, 
objectively reducing the diurnal somnolence, plasma BNP 
levels (a marker of heart failure severity) and the excretion 
of urinary metadrenaline30. It improved the quality of sleep 
(by increasing total sleep time, sleep efficiency, percentage of 
REM and slow wave sleep and decreasing the brief awakening 
index) and reduced AHI and desaturations, when compared 
to controls. There were significant differences in some of these 
parameters in comparison to CPAP31.
Conclusion
Although it is the most studied treatment modality, the use 
of CPAP in CSR is still controversial and the experience of this 
treatment in Brazil is still scarce, as CPAP is not provided by 
the public Health Services and most patients have difficulty 
to buy it. O2 is an option for patients who are intolerant to 
CPAP or who cannot use it for any other reason. However, 
the long-term survival of this treatment modality has yet to 
be assessed. The other types of treatment reported here need 
further studies. CSR is a frequent event in cardiopaths and it is 
associated with a worse prognosis; thus, the correct diagnosis 
and treatment are of utmost importance. 
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